Clinical Trials
45 trialsDinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
National Cancer Institute (NCI)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
National Cancer Institute (NCI)
Personalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
St. Jude Children's Research Hospital
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
City of Hope Medical Center
Haplo-Cord HSCT for AML/MDS
Fujian Medical University Union Hospital
MASTER-2
University of Alabama at Birmingham
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
City of Hope Medical Center
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
SWOG Cancer Research Network
ABCD-NK
Washington University School of Medicine
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
First Affiliated Hospital of Zhejiang University
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
DEL-LIVER
Delcath Systems Inc.
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
M.D. Anderson Cancer Center
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Fred Hutchinson Cancer Center
A Study to Give Treatment Inside the Eye to Treat Retinoblastoma
Children's Oncology Group
ADAPT
University of California, Irvine
SHARON
General Oncology, Inc.
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
RETINO 2018
Institut Curie
Auto Stem Cell Transplant for Lymphoma Patients
Masonic Cancer Center, University of Minnesota
Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
Masonic Cancer Center, University of Minnesota
IS-free Treg HaploHCT
Dana-Farber Cancer Institute
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Ruijin Hospital
Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant
Washington University School of Medicine
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
City of Hope Medical Center
Personalized Autologous Transplant for Multiple Myeloma
Emory University
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma
Eye & ENT Hospital of Fudan University
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
Shanghai Jiao Tong University School of Medicine
Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan
Shanghai Jiao Tong University School of Medicine
SCRIPT-AML
Vastra Gotaland Region
TreoMel
Insel Gruppe AG, University Hospital Bern
HLA
University of Liege
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Topotecan and Melphalan for Retinoblastoma
Sun Yat-sen University
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
St. Anna Kinderkrebsforschung